Artera vs GRAIL

The NHS-Galleri randomized trial missed its primary endpoint, per 2026 coverage in Cancer Discovery and the BMJ, while the FDA advisory panel still voted 7 to 2, with one abstention, that Galleri's benefits outweigh its risks. Galleri's own site says the test has not been cleared or approved by the FDA. Primary care physicians adding a cancer-signal blood test for patients over 50 would order it as an addition to guideline-recommended screening, and it looks for signals from more than 50 cancer types.

Artera suits a urologist with a prostate biopsy in hand. ArteraAI Prostate is a De Novo-authorized software device, and the commercial test runs in Artera's CLIA lab on the same platform. A Lancet Digital Health external validation in advanced prostate cancer and a BMC Cancer multicentre implementation trial back it, though many authors are Artera-affiliated. A primary care physician ordering a screening blood test and a urologist ordering a prostate prognosis are making separate purchases, one before any diagnosis and one after a biopsy.